Market Place
Sourcing Support
Belite Bio Announces Doses First Patient In DRAGON II Trial
10 Sep 2024 //
GLOBENEWSWIRE
Belite Bio Reports Q2 2024 Results And Corporate Update
09 Aug 2024 //
GLOBENEWSWIRE
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant
12 Jun 2024 //
GLOBENEWSWIRE
Belite Bio Q1 2024 Financials, Corporate Update
13 May 2024 //
GLOBENEWSWIRE
Belite Bio KOL Webinar On STGD1, GA And Tinlarebant
06 May 2024 //
GLOBENEWSWIRE
Belite Presents More Tinlarebant Phase 2 Stargardt Data At ARVO
06 May 2024 //
GLOBENEWSWIRE
Belite Bio To Present At ARVO 2024 Annual Meeting
01 May 2024 //
GLOBENEWSWIRE
Belite Bio Announces PMDA Subof Tinlarebant for Stargardt Disease Trial in Japan
22 Mar 2024 //
GLOBENEWSWIRE
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant
06 Nov 2023 //
GLOBENEWSWIRE
Belite Doses First Subject in Phase 3 Trial Evaluating Oral Tinlarebant for GA
27 Jul 2023 //
GLOBENEWSWIRE
Belite Completes Enrollment in Phase 3 DRAGON Trial Evaluating Tinlarebant
24 Jul 2023 //
GLOBENEWSWIRE
Belite Bio Presented 18-Month Interim Data from a 24-Month Ph2 Tinlarebant
25 Apr 2023 //
GLOBENEWSWIRE
Belite Bio Finalizes Ph3 Trial Plans for Advanced Dry AMD with Tinlarebant
18 Nov 2022 //
GLOBENEWSWIRE
Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008
22 Aug 2022 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.